T-CURX completes first closing of a 20 million dollar Series A financing

The German biotech company T-CURX GmbH has announced the first closing of its Series A financing round. A total of 20 million US dollars (around 17.7 million euros) is to be raised. The round is led by Swiss venture capital investor BiomedVC and will be used to accelerate the clinical development of several CAR-T programs and to expand a proprietary non-viral CAR-T platform.

International investor consortium from Europe and Asia

I am very pleased that with T-CURX we were able to convince a renowned international investor consortium of the added value of the non-clinical and clinical CAR-T technology and our CAR-T pipeline.

Dr. Ulf Grawunder, CEO and co-founder of T-CURX GmbH

In addition to BiomedVC, Bayern Kapital, HighLight Capital (HLC) and the i&iBio Fund are participating in the financing round. The consortium is complemented by existing and new private investors. The capital is intended in particular to drive forward the clinical development of non-viral CAR-T therapies in acute myeloid leukemia (AML) and solid tumor indications.

Focus on non-viral CAR-T technologies

T-CURX is pursuing a technology-driven approach to produce CAR-T cell therapies without viral vectors. The company is developing both ex-vivo CAR-T programs in the clinical phase and proprietary platform technologies for the non-viral, potentially in vivo-based generation of CAR-T cells. The aim is to make CAR-T therapies more economical, scalable and therefore more widely accessible.

CAR-T cell therapy has the potential to revolutionize the treatment of various cancers, including AML, a particularly widespread and aggressive type of leukemia.

Monika Steger, Managing Director of Bayern Kapital

Spin-off from cutting-edge university research

T-CURX was founded in 2017 and is a spin-off from the laboratory of Prof. Michael Hudecek at the University of Würzburg. Hudecek is considered one of Europe's leading experts and pioneers in the field of non-viral CAR-T cell therapies. The company is based in Würzburg and Munich and is led by co-founder and CEO Dr. Ulf Grawunder, an experienced serial entrepreneur in the biotech sector.

Democratization of CAR-T therapies as a long-term vision

With its virus-free sleeping beauty transposon technology, T-CURX is pursuing the goal of reducing the high costs and complex production processes of traditional CAR therapies. The funding that has now been secured should enable the further development of this platform and pave the way for broader clinical and commercial application.